Table 3.

Comparison between different risk scores

	D:A:D* (n=362) n (%)	FRS† (n=382) n (%)	ASCVD‡ n (%)	QRISK2§ (n=376) n (%)	RAMA-EGAT (n=376) n (%)
Risk profile
High	9 (2.5)		33 (16.3)
Intermediate	123 (33.9)		19 (9.4)
Low	230 (63.5)		150 (74.3)
Kappa statistic	1	–	0.25	–	–
Risk per cent
>20		12 (3.1)	3 (1.5)	13 (3.5)	2 (0.5)
10–20		28 (7.3)	18 (8.9)	30 (7.9)	62 (16.5)
<10		342 (89.5)	181 (89.6)	333 (88.6)	312 (82.9)
Kappa statistic	–	1	0.48	0.67	0.57
Percent difference in 10-year cumulative risk scores ¶		12.8	–	36.5
Lifetime risk
<50%	–	355 (92.9)	292 (80.9)	252 (67)	–
≥50%		27 (7.1)	69 (19.1)	124 (32.9)
Statin recommended
Yes	–	–	64 (32.0)	43 (11.4)	–
No			138 (68.0)	333 (88.6)

All scores except the D:A:D score estimate a 10-year CVD risk.

*D:A:D score estimates a 5 -year CVD risk. High risk (>5%), intermediate risk (1%–5%), low risk (<1%).

†FRS: Lifetime risk was derived using the Framingham 30-year CVD risk with lipids. Ten-year risk was derived using the score with lipids.

‡ASCVD: 10-year risk estimation and statin recommendations for 40–79 years (n=202). Lifetime risk estimated for 20–59 years (n=361). High risk (≥7.5%), intermediate risk (5%–7.5%), low risk (<5%).

§QRISK2: Lifetime risk estimation was done using the QRISK lifetime CVD risk calculator, statin recommendations were based on NICE guidelines.

¶Per cent difference was calculated as: ((cumulative CVD risk of study population - cumulative CVD risk of normal population)/cumulative CVD risk of normal population)*100. The risks for the normal populations were abstracted from the risk calculators of the respective scores from their official websites.

ASCVD, Atherosclerotic Cardiovascular; CVD, cardiovascular disease; D:A:D, Data Collection on Adverse Effects of Anti-HIV Drugs Study; FRS: Framingham risk score; NICE, National Institute for Health and Care Excellence; RAMA-EGAT, Ramathibodi—Electricity Generating Authority of Thailand score.